Nanjing Leads Biolabs Co., Ltd. (SEHK: 9887)
Health Care · Biotechnology · CN
HK$45.56
-9.69% today · -35.3% 1Y
Nanjing Leads Biolabs Co., Ltd. (SEHK: 9887) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.13B and employs 244 people.
Over the last twelve months the share price has lost 35.3%, trading between 43.62 and 97.50.
Tweenvest scores Nanjing Leads Biolabs Co., Ltd. across four factors: quality 54/100, value 47/100. Its strongest factor is quality.
9887 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.13B
- Revenue (TTM)
- $31.39M
- P/E
- —
- EPS
- -1.37
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$97.50
- 52-week low
- HK$43.62
- Avg volume (3M)
- —
- Shares outstanding
- 195.12M
- Employees
- 244
- Next earnings
- —
About Nanjing Leads Biolabs Co., Ltd.
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
- ISIN
- CNE1000070H8
- Founded
- 2012
- Listed since
- Jul 25, 2025
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| HBM Holdings LimitedSEHK: 2142 | $1.17B | HK$11.14 | -17.11% |
| Aimed Bio Inc.KOSDAQ: A0009K0 | $1.17B | ₩24,250.00 | -2.22% |
| Bicara Therapeutics Inc.NasdaqGM: BCAX | $1.16B | $17.50 | -0.74% |
| Amoy Diagnostics Co., Ltd.SZSE: 300685 | $1.16B | CN¥20.30 | -4.87% |
| L&C BIO Co.,LTDKOSDAQ: A290650 | $1.13B | ₩56,400.00 | +5.03% |
| Janux Therapeutics, Inc.NasdaqGM: JANX | $1.12B | $18.39 | +8.62% |
| HOB Biotech Group Corp.,LtdSHSE: 688656 | $1.12B | CN¥120.00 | -8.90% |
| China Resources Boya Bio-pharmaceutical Group Co.,LtdSZSE: 300294 | $1.12B | CN¥14.88 | -0.40% |
Figures last refreshed Oct 11, 2026.